Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26


Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.

Gulati S, Desai J, Palackdharry SM, Morris JC, Zhu Z, Jandarov R, Riaz MK, Takiar V, Mierzwa M, Gutkind JS, Molinolo A, Desai PB, Sadraei NH, Wise-Draper TM.

Cancer. 2019 Oct 18. doi: 10.1002/cncr.32539. [Epub ahead of print]


IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma.

Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto N, Kitahara S, Yoshino H, Yamashita D, Sumita K, Wolfe K, Lange L, Ikeda S, Shimada H, Minami N, Malhotra A, Morioka S, Ban Y, Asano M, Flanary VL, Ramkissoon A, Chow LML, Kiyokawa J, Mashimo T, Lucey G, Mareninov S, Ozawa T, Onishi N, Okumura K, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Kanemura Y, Smith EP, Anastasiou D, Wakimoto H, Holland EC, Yong WH, Horbinski C, Nakano I, DeBerardinis RJ, Bachoo RM, Mischel PS, Yasui W, Suematsu M, Saya H, Soga T, Grummt I, Bierhoff H, Sasaki AT.

Nat Cell Biol. 2019 Aug;21(8):1003-1014. doi: 10.1038/s41556-019-0363-9. Epub 2019 Aug 1.


Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013.

Ribrag V, Avigan DE, Green DJ, Wise-Draper T, Posada JG, Vij R, Zhu Y, Farooqui MZH, Marinello P, Siegel DS.

Br J Haematol. 2019 Aug;186(3):e41-e44. doi: 10.1111/bjh.15888. Epub 2019 Apr 1. No abstract available.


High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma.

Haque S, Karivedu V, Riaz MK, Choi D, Roof L, Hassan SZ, Zhu Z, Jandarov R, Takiar V, Tang A, Wise-Draper T.

Oral Oncol. 2019 Jan;88:9-15. doi: 10.1016/j.oraloncology.2018.11.010. Epub 2018 Nov 16.


A defect in KCa3.1 channel activity limits the ability of CD8+ T cells from cancer patients to infiltrate an adenosine-rich microenvironment.

Chimote AA, Balajthy A, Arnold MJ, Newton HS, Hajdu P, Qualtieri J, Wise-Draper T, Conforti L.

Sci Signal. 2018 Apr 24;11(527). pii: eaaq1616. doi: 10.1126/scisignal.aaq1616.


Differential expression and prognostic value of long non-coding RNA in HPV-negative head and neck squamous cell carcinoma.

Haque SU, Niu L, Kuhnell D, Hendershot J, Biesiada J, Niu W, Hagan MC, Kelsey KT, Casper KA, Wise-Draper TM, Medvedovic M, Langevin SM.

Head Neck. 2018 Jul;40(7):1555-1564. doi: 10.1002/hed.25136. Epub 2018 Mar 25.


Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma.

Wise-Draper T, Sendilnathan A, Palackdharry S, Pease N, Qualtieri J, Butler R, Sadraei NH, Morris JC, Patil Y, Wilson K, Mark J, Casper K, Takiar V, Lane A, Privette Vinnedge L.

Transl Oncol. 2018 Feb;11(1):168-174. doi: 10.1016/j.tranon.2017.12.001. Epub 2017 Dec 28.


Comprehensive microRNA-sequencing of exosomes derived from head and neck carcinoma cells in vitro reveals common secretion profiles and potential utility as salivary biomarkers.

Langevin S, Kuhnell D, Parry T, Biesiada J, Huang S, Wise-Draper T, Casper K, Zhang X, Medvedovic M, Kasper S.

Oncotarget. 2017 Jul 27;8(47):82459-82474. doi: 10.18632/oncotarget.19614. eCollection 2017 Oct 10.


A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.

Wise-Draper TM, Moorthy G, Salkeni MA, Karim NA, Thomas HE, Mercer CA, Beg MS, O'Gara S, Olowokure O, Fathallah H, Kozma SC, Thomas G, Rixe O, Desai P, Morris JC.

Target Oncol. 2017 Jun;12(3):323-332. doi: 10.1007/s11523-017-0482-9.


Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer.

Chimote AA, Hajdu P, Sfyris AM, Gleich BN, Wise-Draper T, Casper KA, Conforti L.

Cancer Res. 2017 Jan 1;77(1):53-61. doi: 10.1158/0008-5472.CAN-16-2372. Epub 2016 Nov 4.


The current status of oncolytic viral therapy for head and neck cancer.

Old MO, Wise-Draper T, Wright CL, Kaur B, Teknos T.

World J Otorhinolaryngol Head Neck Surg. 2016 Jul 22;2(2):84-89. doi: 10.1016/j.wjorl.2016.05.009. eCollection 2016 Jun. Review.


The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.

Riaz MK, Bal S, Wise-Draper T.

J Surg Oncol. 2016 Sep;114(3):323-8. doi: 10.1002/jso.24333. Epub 2016 Jul 4. Review.


Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer.

Pease NA, Wise-Draper T, Privette Vinnedge L.

J Oncol. 2015;2015:106517. doi: 10.1155/2015/106517. Epub 2015 Sep 6. Review.


Oncolytic virotherapy for head and neck cancer: current research and future developments.

Malhotra A, Sendilnathan A, Old MO, Wise-Draper TM.

Oncolytic Virother. 2015 Jul 20;4:83-93. doi: 10.2147/OV.S54503. eCollection 2015. Review.


Human papillomavirus induced transformation in cervical and head and neck cancers.

Adams AK, Wise-Draper TM, Wells SI.

Cancers (Basel). 2014 Sep 15;6(3):1793-820. doi: 10.3390/cancers6031793. Review.


Lymphoma presenting as secondary HLH: a review with a tale of two cases.

Ghose A, Yellu M, Wise-Draper T, Sharma D, Qualtieri J, Latif T, Medlin S.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e187-93. doi: 10.1016/j.clml.2014.06.025. Epub 2014 Jun 21. Review. No abstract available.


DEK promotes HPV-positive and -negative head and neck cancer cell proliferation.

Adams AK, Hallenbeck GE, Casper KA, Patil YJ, Wilson KM, Kimple RJ, Lambert PF, Witte DP, Xiao W, Gillison ML, Wikenheiser-Brokamp KA, Wise-Draper TM, Wells SI.

Oncogene. 2015 Feb 12;34(7):868-77. doi: 10.1038/onc.2014.15. Epub 2014 Mar 10.


A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.

Bahassi el M, Li YQ, Wise-Draper TM, Deng L, Wang J, Darnell CN, Wilson KM, Wells SI, Stambrook PJ, Rixe O.

Eur J Cancer. 2013 Jul;49(10):2345-55. doi: 10.1016/j.ejca.2013.03.005. Epub 2013 Apr 8.


Future directions and treatment strategies for head and neck squamous cell carcinomas.

Wise-Draper TM, Draper DJ, Gutkind JS, Molinolo AA, Wikenheiser-Brokamp KA, Wells SI.

Transl Res. 2012 Sep;160(3):167-77. doi: 10.1016/j.trsl.2012.02.002. Epub 2012 Feb 28.


The human DEK oncogene regulates DNA damage response signaling and repair.

Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmüller L, Wells SI.

Nucleic Acids Res. 2011 Sep 1;39(17):7465-76. doi: 10.1093/nar/gkr454. Epub 2011 Jun 7.


Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.

Wise-Draper TM, Mintz-Cole RA, Morris TA, Simpson DS, Wikenheiser-Brokamp KA, Currier MA, Cripe TP, Grosveld GC, Wells SI.

Cancer Res. 2009 Mar 1;69(5):1792-9. doi: 10.1158/0008-5472.CAN-08-2304. Epub 2009 Feb 17.


DEK proto-oncogene expression interferes with the normal epithelial differentiation program.

Wise-Draper TM, Morreale RJ, Morris TA, Mintz-Cole RA, Hoskins EE, Balsitis SJ, Husseinzadeh N, Witte DP, Wikenheiser-Brokamp KA, Lambert PF, Wells SI.

Am J Pathol. 2009 Jan;174(1):71-81. doi: 10.2353/ajpath.2009.080330. Epub 2008 Nov 26.


Coordinate regulation of Fanconi anemia gene expression occurs through the Rb/E2F pathway.

Hoskins EE, Gunawardena RW, Habash KB, Wise-Draper TM, Jansen M, Knudsen ES, Wells SI.

Oncogene. 2008 Aug 14;27(35):4798-808. doi: 10.1038/onc.2008.121. Epub 2008 Apr 28.


Papillomavirus E6 and E7 proteins and their cellular targets.

Wise-Draper TM, Wells SI.

Front Biosci. 2008 Jan 1;13:1003-17. Review.


Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.

Wise-Draper TM, Allen HV, Jones EE, Habash KB, Matsuo H, Wells SI.

Mol Cell Biol. 2006 Oct;26(20):7506-19. Epub 2006 Aug 7.


The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7.

Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Münger K, Wells SI.

J Virol. 2005 Nov;79(22):14309-17.

Supplemental Content

Loading ...
Support Center